A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk

被引：0
|
作者：
Choueiri, Toni K.
Albiges, Laurence
Powles, Thomas
Scheffold, Christian
Wang, Fong
Motzer, Robert J.
机构：
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Queen Mary Univ London, Barts Canc Inst, London, England
[5] Exelixis Inc, Alameda, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS767
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
    Choueiri, T. K.
    Powles, T. B.
    Albiges, L.
    Burotto, M.
    Szczylik, C.
    Zurawski, B.
    Riuz, E. Yanez
    Maruzzo, M.
    Zaizar, A. Suarez
    Fein, L. E.
    Schutz, F. A. Barros
    Heng, D. Y. C.
    Wang, F.
    Mataveli, F.
    Chang, Y. L.
    van Kooten Losio, M.
    Rodriguez, C. Suarez
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1431
  • [2] A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
    Choueiri, Toni K.
    Albiges, Laurence
    Powles, Thomas
    Scheffold, Christian
    Wang, Fong
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A PHASE 3 STUDY (COSMIC-313) OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK
    Choueiri, Toni
    Albiges, Laurence
    Powles, Thomas
    Mohamed, Nehal
    Wang, Fong
    Motzer, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A209 - A209
  • [4] Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
    Albiges, Laurence
    Motzer, Robert J.
    Trevino, Sergio
    Kanesvaran, Ravindran
    Centkowski, Piotr
    Reimers, Melissa A.
    Sade, Juan Pablo
    Pouessel, Damien
    Biscaldi, Elisa
    Esteban, Emilio
    Arranz Arija, Jose Angel
    Tykodi, Scott S.
    Ma, Haijun
    Zhou, Lei
    Van Kooten Losio, Maximiliano A. G.
    Simmons, Andrew
    Rangwala, Fatima A.
    Braun, David A.
    Choueiri, Toni K.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [5] Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.
    Powles, Thomas
    Motzer, Robert J.
    Albiges, Laurence
    Suarez, Cristina
    Schutz, Fabio A. B.
    Heng, Daniel Yick Chin
    Chevreau, Christine
    Kanesvaran, Ravindran
    Gurney, Howard
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    Losio, Maximiliano van Kooten
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).
    McGregor, Bradley Alexander
    Xie, Wanling
    Bilen, Mehmet Asim
    Braun, David A.
    Xu, Wenxin
    Ravi, Praful
    Heath, Elisabeth I.
    McDermott, David F.
    Mckay, Rana R.
    Hammers, Hans J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] UPDATED LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA (1L ARCC)
    Qendri, V
    May, J.
    Malcolm, B.
    Ejzykowicz, F.
    Kurt, M.
    Cakar, E.
    Klijn, S.
    VALUE IN HEALTH, 2020, 23 : S520 - S520
  • [9] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
    Grimm, Marc-Oliver
    Mcdermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Rodriguez-Cid, Jeronimo
    Ishii, Yuko
    Mchenry, Brent
    Rini, Brian I.
    Tannir, Nizar M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
  • [10] A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
    Wang, Jianbo
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Goswami, Sangeeta
    Msaouel, Pavlos
    Alhalabi, Omar
    Hahn, Andrew Warren
    Kovitz, Craig A.
    Jana, Bagi Rp
    Araujo, John C.
    Gao, Jianjun
    Zurita, Amado J.
    Jonasch, Eric
    Corn, Paul Gettys
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345